AbbVie (ABBV) Stock Analysis
This is a peer-relative look at AbbVie (ABBV): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | ABBV |
|---|---|
| Name | AbbVie Inc. |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology |
| GICS Sub-Industry | Biotechnology |
| Market Capitalization | 452.48 billion USD |
| Currency | USD |
| Exchange | NYSE |
| Listing Date | January 2, 2013 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| Total Return (1Y) | 42.84% | 47.89% |
| Total Return (3Y, Annualized) | 25.49% | 9.98% |
| Total Return (5Y, Annualized) | 21.34% | -4.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 25.90% | 69.09% |
| Beta (5Y) | 0.30 | 0.91 |
| Max Drawdown (5Y) | -21.92% | -82.64% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 1.50 | 0.81 |
| Sortino Ratio (1Y) | 2.41 | 1.37 |
Profitability
ROE (TTM)
No usable ROE is available for AbbVie (ABBV) this period, so the shareholder-equity return read is skipped.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 99.40%
- Q3
- 2.50%
- Median
- -31.42%
- Q1
- -62.21%
- Min
- -157.07%
- ABBV
- --
Largest peers
- LLY
- 107.46%
- NVO
- 71.40%
- NVS
- 34.93%
- AZN
- 23.48%
- MRK
- 18.94%
- ABBV
- --
- JNJ
- --
Net Margin (TTM)
AbbVie (ABBV) keeps 5.79% of revenue as net profit, putting net margin in the upper peer quartile. After operating costs, interest, and taxes, more of each sales dollar reaches shareholders than it does at most industry peers.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79%
Group distribution
- Max
- 11.75%
- ABBV
- 5.79%
- Q3
- 2.69%
- Median
- 0.00%
- Q1
- -3.38%
- Min
- -11.53%
Largest peers
- NVO
- 37.21%
- LLY
- 34.99%
- NVS
- 23.92%
- JNJ
- 21.48%
- AZN
- 17.19%
- MRK
- 13.59%
- ABBV
- 5.79%
Operating Margin (TTM)
AbbVie (ABBV) turns 32.16% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.16%
Group distribution
- Max
- 100.30%
- ABBV
- 32.16%
- Q3
- 4.66%
- Median
- 0.00%
- Q1
- -121.08%
- Min
- -309.54%
Largest peers
- NVO
- 61.57%
- LLY
- 49.39%
- MRK
- 38.60%
- ABBV
- 32.16%
- NVS
- 30.48%
- JNJ
- 28.61%
- AZN
- 27.94%
Profitability Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| ROE (TTM) | -- | -31.42% |
| ROA (TTM) | 10.03% | -15.76% |
| Net Margin (TTM) | 5.79% | 0.00% |
| Operating Margin (TTM) | 32.16% | 0.00% |
| Gross Margin (TTM) | 72.03% | 30.12% |
Growth
Revenue Growth
AbbVie (ABBV) grew revenue 8.57%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.
EPS Growth
AbbVie (ABBV) grew earnings per share -1.26%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.
Growth Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | 11.61% |
| Revenue Growth (3Y CAGR) | 1.75% | 10.74% |
| EPS Growth (YoY) | -1.26% | 1.77% |
| EPS Growth (3Y CAGR) | -29.13% | 3.04% |
Financial Strength
Current Ratio (MRQ)
AbbVie (ABBV) has current ratio of 0.80, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.80
Group distribution
- Max
- 26.16
- Q3
- 12.33
- Median
- 5.81
- Q1
- 2.71
- ABBV
- 0.80
- Min
- 0.28
Largest peers
- LLY
- 1.50
- MRK
- 1.30
- AZN
- 0.91
- NVS
- 0.85
- ABBV
- 0.80
- NVO
- 0.79
- JNJ
- --
Debt / Equity (MRQ)
No usable debt-to-equity ratio is available for AbbVie (ABBV) this period, so the balance-sheet leverage read is skipped.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 1.60
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
Largest peers
- LLY
- 1.39
- NVS
- 1.21
- MRK
- 1.07
- NVO
- 0.72
- AZN
- 0.72
- JNJ
- 0.68
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 0.80 | 5.81 |
| Debt / Equity (MRQ) | -- | 0.15 |
| Net Debt / EBITDA | 2.12 | 1.05 |
Dividends
Dividend Yield (TTM)
AbbVie (ABBV) has dividend yield of 2.66%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.66%
Group distribution
- ABBV
- 2.66%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVO
- 23.58%
- ABBV
- 2.66%
- MRK
- 2.64%
- JNJ
- 2.11%
- AZN
- 1.95%
- LLY
- 0.54%
- NVS
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) has payout ratio of 325.98%, meaning dividends exceeded current-period earnings. The gap would need to be covered by cash, retained earnings, financing, or other sources, so earnings alone do not support the payout.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
325.98%
Group distribution
- ABBV
- 325.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- ABBV
- 325.98%
- MRK
- 93.52%
- NVS
- 67.91%
- JNJ
- 60.79%
- AZN
- 47.70%
- NVO
- 42.59%
- LLY
- 22.13%
Dividend Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 2.66% | 0.00% |
| Dividend Payout Ratio (TTM) | 325.98% | 0.00% |
Valuation
P/E Ratio (TTM)
AbbVie (ABBV) trades at P/E ratio of 123.72, above the peer range for its industry. The market is paying unusually heavily for TTM earnings relative to comparable companies.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
123.72
Group distribution
- ABBV
- 123.72
- Max
- 79.93
- Q3
- 47.39
- Median
- 25.31
- Q1
- 15.26
- Min
- 2.05
Largest peers
- ABBV
- 123.72
- LLY
- 40.81
- MRK
- 35.07
- JNJ
- 28.91
- AZN
- 24.76
- NVS
- 21.40
- NVO
- 11.90
P/S Ratio (TTM)
AbbVie (ABBV) trades at 7.20 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.20
Group distribution
- Max
- 63.16
- Q3
- 28.29
- Median
- 8.07
- ABBV
- 7.20
- Q1
- 3.52
- Min
- 0.01
Largest peers
- LLY
- 14.51
- ABBV
- 7.20
- JNJ
- 6.16
- NVS
- 5.17
- MRK
- 4.74
- AZN
- 4.35
- NVO
- 0.67
P/B Ratio (MRQ)
AbbVie (ABBV) has negative P/B ratio of -67.99, which means reported book equity is negative. Price-to-book breaks down in this situation and should not be used as a valuation signal.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-67.99
Group distribution
- Max
- 16.09
- Q3
- 7.48
- Median
- 3.80
- Q1
- 1.72
- Min
- -5.70
- ABBV
- -67.99
Largest peers
- LLY
- 33.66
- NVS
- 7.62
- JNJ
- 7.43
- NVO
- 7.08
- MRK
- 6.80
- AZN
- 5.54
- ABBV
- -67.99
Valuation Metrics
| Metric | Current stock: ABBV | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | 123.72 | 25.31 |
| P/S Ratio (TTM) | 7.20 | 8.07 |
| P/B Ratio (MRQ) | -67.99 | 3.80 |
| Free Cash Flow Yield (TTM) | 4.60% | -2.02% |